ArticleOpen forum infectious diseases2019
Appropriate Treatment for Bloodstream Infections Due to Carbapenem-Resistant
Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 28 citations in OpenAlex.
- Comparison of Effectiveness between Ceftazidime/Avibactam and Other Active Therapies for Oxacillinase-48-Producing Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Taiwan.Infectious diseases and therapy · 2025Article
- Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China.BMC infectious diseases · 2025Article
- Guidelines for Antibacterial Treatment of Carbapenem-Resistant Enterobacterales Infections.Infection & chemotherapy · 2024Review
- Evaluating Risk Factors for Clinical Failure Among Tigecycline-Treated Patients.Infection and drug resistance · 2024Article
- Clinical characteristics of carbapenem-resistantBMJ open · 2023Article
- Secondary bacterial infection caused by ST16 NDM-1 and OXA-48-producing colistin and carbapenem-resistant Klebsiella pneumoniae treated with tigecycline in a pregnant woman with COVID-19.Journal of pharmaceutical policy and practice · 2023Article
- Risk Factors for the Development of Colistin Resistance during Colistin Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections.Microbiology spectrum · 2022Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.Frontiers in cellular and infection microbiology · 2022Review
- Clinical and Microbiological Characteristics of Bacteremic Pneumonia Caused byFrontiers in cellular and infection microbiology · 2022Article
- Drug Susceptibility and Molecular Epidemiology ofFrontiers in medicine · 2021Article
- Does Antimicrobial Therapy Affect Mortality of Patients with Carbapenem-ResistantMicroorganisms · 2020Article
- Epigenomics, genomics, resistome, mobilome, virulome and evolutionary phylogenomics of carbapenem-resistantMicrobial genomics · 2020Article
- The Effect of Host Immunity on Predicting the Mortality of Carbapenem-Resistant Organism Infection.Frontiers in cellular and infection microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
Abstract
backgroundIn a multicenter study from Taiwan, we aimed to investigate the outcome of patients who received different antimicrobial therapy in carbapenem-resistant Enterobacteriaceae bloodstream infections and proposed a new definition for tigecycline use.
methodsPatients from 16 hospitals in Taiwan who received appropriate therapy for bloodstream infections due to carbapenem-resistant
resultsSixty-four cases with carbapenem-resistant
conclusionsTigecycline monotherapy was a choice if the strains exhibited MIC ≤0.5 mg/L, and colistin monotherapy was not suitable. Our findings can initiate additional clinical studies regarding the efficacy of tigecycline in carbapenem-resistant Enterobacteriaceae infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.